Kymera Therapeutics Inc. (KYMR)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XKLS 
Kymera Therapeutics: Well-Funded Pipeline Enters A Defining Clinical Phase
Kymera Therapeutics remains focused on pipeline progression despite a Q4 revenue miss and widening net loss, supported by a robust $1.6 billion cash position. R&D investment surged to $316.6 million in FY25, reflecting aggressive advancement of KT-621 and KT-579 into mid-stage trials, prioritizing long-term value over near-term profitability. KT-621's Phase 2b trials in atopic dermatitis and eosinophilic asthma are key 2027 catalysts; KT-579's Phase 1 data in autoimmune diseases is expected in 2H26.
Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway
KYMR posts wider-than-expected Q4 loss as R&D jumps and collaboration revenues fall, but $1.6B cash haul and KT-621 progress bolster pipeline outlook.
Kymera Therapeutics, Inc. (KYMR) Q4 2025 Earnings Call Transcript
Kymera Therapeutics, Inc. (KYMR) Q4 2025 Earnings Call Transcript
Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates
Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.97 per share versus the Zacks Consensus Estimate of a loss of $0.77. This compares to a loss of $0.88 per share a year ago.
KYMR Initiates Dosing in Mid-Stage Asthma Study of Lead Candidate
Kymera Therapeutics begins phase IIb dosing of oral KT-621 in eosinophilic asthma patients, targeting STAT6, with top-line BREADTH study data expected in late 2027.
Kymera Therapeutics (KYMR) Upgraded to Buy: Here's Why
Kymera Therapeutics (KYMR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026?
KYMR rallied 82% in a year as KT-621 delivered strong phase Ib BroADen data and earned FDA Fast Track for atopic dermatitis.
KYMR Stock Surges on Upbeat Data From KT-621 Atopic Dermatitis Study
Kymera jumps after phase Ib study data show KT-621 delivers strong STAT6 degradation and broad clinical activity in patients with atopic dermatitis.
This Drugmaker's Stock Is Soaring Over 40% Monday
Kymera Therapeutics (KYMR) shares surged over 40% to an all-time high Monday afternooon after the drugmaker reported positive results from an early test of an oral anti-inflammatory drug.
Kymera's KT-621 Shines: Phase 1b Data Boosts Momentum
Kymera Therapeutics, Inc. reported robust Phase 1b results for KT-621, showing deep STAT6 degradation and strong clinical efficacy in atopic dermatitis. KT-621 demonstrated a favorable safety profile, rapid onset, and meaningful biomarker and symptom improvements, supporting advancement to Phase 2b trials in AD and asthma. KYMR's $4.8B market cap reflects its validated protein-degradation platform and KT-621's commercial potential in large, crowded Type-2 inflammatory disease markets.
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock?
Kymera Therapeutics, Inc. (KYMR) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Kymera Therapeutics, Inc. (KYMR) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
